Medtronic Looks Set for Takeoff

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Medical apparatus manufacturer Medtronic (NYSE: MDT  ) posted flat first-quarter revenues but saw its earnings fall marginally. However, the company managed to meet Street expectations and its shares jumped 6%.

Revenue for the quarter grew 7% to $4.04 billion; however, if we take the favorable currency out of the equation, it only grew a meager 2%. The company reported 25% growth in revenue from emerging markets like China and the Middle East, but falling demand for Medtronic’s heart defibrillators and spinal products in the U.S. market offset much of that growth. Still, operating income jumped 9% to $1.18 billion in the quarter.

The company has taken steps to bounce back in the U.S. market through its improved ICD Protecta. It saw sales of its spinal devices decline after a medical journal was highly critical of Medtronic’s Infuse, and the company expects this segment to go down further. However, Medtronic is upbeat about its prospects outside the U.S., as its international revenue accounted for 46% of total sales.

The company has been a regular dividend payer and is inclined toward returning cash to its shareholders. In fact, Medtronic’s dividend yield of 2.8% stands a cut above peers Stryker (NYSE: SYK  ) , Baxter (NYSE: BAX  ) , and St. Jude Medical (NYSE: STJ  ) . A low payout ratio of 32% and 33-year history of dividend increases should give investors added confidence in this dividend dynamo.

The Foolish takeaway
The main sticking point for Medtronic is weak demand in the U.S. Apart from that, the company is doing well to diversify itself both in terms of product innovation and geographical expansion, and looks set for a good year ahead.

To stay in touch with the latest developments on Medtronic, add it to My Watchlist.

Harsh Chauhan doesn’t own any shares in the companies mentioned in this article. The Motley Fool owns shares of St. Jude Medical and Medtronic. Motley Fool newsletter services have recommended buying shares of Stryker. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1546652, ~/Articles/ArticleHandler.aspx, 10/27/2016 7:08:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,169.68 -29.65 -0.16%
S&P 500 2,133.04 -6.39 -0.30%
NASD 5,215.97 -34.29 -0.65%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:02 PM
MDT $81.13 Up +0.01 +0.01%
Medtronic CAPS Rating: *****
BAX $46.82 Down -0.62 -1.31%
Baxter CAPS Rating: ****
STJ $79.01 Up +0.31 +0.39%
St. Jude Medical CAPS Rating: **
SYK $109.72 Down -0.17 -0.15%
Stryker CAPS Rating: *****